Current Colorectal Cancer Reports

, Volume 5, Issue 2, pp 65–66

Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial

  • Axel Grothey
Clinical Trials Report

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  • Axel Grothey

There are no affiliations available

Personalised recommendations